Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2015

Jurmeister Philipp, Lenze Dido, Berg Erika, Mende Stefanie, Schäper Frank, Kellner Udo, Herbst Hermann, Sers Christine, Budczies Jan, Dietel Manfred, Hummel Michael, von Laffert Maximilian

Abstract excerpt

OBJECTIVES: ALK, MET and ROS1 are prognostic and predictive markers in NSCLC, which need to be implemented in daily routine. To evaluate different detection approaches and scoring systems for optimal stratification of patients eligible for mutation testing in the future, we screened a large and unselected cohort of NSCLCs for all three alterations. MATERIAL AND METHODS: Using tissue microarrays, 473 surgically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Early Detection of Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-met

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 25534130
DOI: 10.1016/j.lungcan.2014.11.018

Genes

MET
ALK
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.PMID 25534130Read ↗

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancerSemantic proximity Read ↗

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive PatternsSemantic proximity Read ↗

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testingSemantic proximity Read ↗

[Clinicopathological significance in non-small cell lung cancer with mutations and co-mutations of EGFR, ALK and ROS1].Semantic proximity Read ↗

A genomic and clinicopathological study of non-small-cell lung cancers with discordant ROS1 gene status by fluorescence in-situ hybridisation and immunohistochemical analysis.Semantic proximity Read ↗

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.Semantic proximity Read ↗

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.Semantic proximity Read ↗

Testing for ROS1 in non-small cell lung cancer: a review with recommendationsSemantic proximity Read ↗

Evaluation of ROS1 expression and rearrangements in a large cohort of early- stage lung cancerSemantic proximity Read ↗

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancerSemantic proximity Read ↗

Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.